阿帕替尼联合化疗对晚期胃癌化疗后进展的疗效及安全性观察

Observation of the efficacy and safety of apatinib combined with chemotherapy on the progression of advanced gastric cancer after chemotherapy

目的分析阿帕替尼联合化疗对晚期胃癌化疗后进展的疗效及安全性观察。方法 98例晚期胃癌患者,按随机数字表法分为对照组和研究组,每组49例。对照组给予伊立替康静脉注射+替吉奥胶囊或静脉注射紫杉醇+替吉奥胶囊,研究组在对照组的基础上结合阿帕替尼化疗方案。比较两组患者临床疗效、不良反应发生情况、化疗前后的肿瘤标志物癌胚抗原(CEA)、糖类抗原CA199(CA-199)水平。结果研究组客观缓解率(ORR)53.06%、疾病控制率(DCR)91.84%均高于对照组的32.65%、77.55%,不良反应发生率14.29%低于对照组的36.73%,差异均具有统计学意义(P<0.05)。化疗后,研究组患者CEA水平(5.18±1.11)ng/ml、CA-199水平(25.14±0.46)U/ml,均低于对照组的(7.18±0.76)ng/ml、(35.13±0.55)U/ml,差异均具有统计学意义(P<0.05)。结论使用阿帕替尼联合化疗治疗晚期胃癌患者,其治疗效果显著,不良反应少,安全性较高,临床上值得推广使用。

Objective To analyze the efficacy and safety of apatinib combined with chemotherapy on the progression of advanced gastric cancer after chemotherapy. Methods A total of 98 patients with advanced gastric cancer were divided into control group and research group according to random numerical table, with 49 cases in each group. The control group was treated with irinotecan intravenous injection + tigio capsule or intravenous paclitaxel + tigio capsule, and the research group was treated with apatinib chemotherapy regimen on the basis of the control group. The clinical efficacy, occurrence of adverse reactions, levels of carcinoembryonic antigen(CEA) and carbohydrate antigen CA199(CA-199) before and after chemotherapy were compared between the two groups. Results The objective remission rate(ORR) 53.06% and disease control rate(DCR) 91.84% of the research group were higher than 32.65% and 77.55% of the control group, and incidence of adverse reactions 14.29% was lower than 36.73% of the control group, and the difference was statistically significant(P<0.05). After chemotherapy, CEA(5.18±1.11) ng/ml and CA-199(25.14±0.46) U/ml of the research group were lower than(7.18± 0.76) ng/ml and(35.13±0.55) U/ml of the control group, and the difference was statistically significant(P<0.05). Conclusion Apatinib combined with chemotherapy shows significant therapeutic effect on advanced gastric cancer patients with less adverse reactions and high safety. It is worthy of clinical promotion and application.